All In Biotech

Drug Trial Radar · NCT07380386

SKB105 for Injection in Advanced Solid Tumors

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB105 for Injection in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

256

Planned (sponsor's estimate)

Start

Mar 5, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 clinical study to evaluate the safety and efficacy of SKB105 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Conditions

  • Advanced Solid Tumors

Interventions

  • SKB105 for injection MonotherapyDrug

    SKB105 for injection monotherapy, iv drip, every 3 weeks (Q3W), until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects achieving Dose-limiting toxicity (DLT)Time frame: From date of initial dose until up to 21 days for treatment
  2. Objective Response Rate (ORR)Time frame: up to 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Shangahi Chest Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.